Medicine
Epclusa 200 mg/50 mg oral pellets
Epclusa 200 mg/50 mg oral pellets is a prescription medicine containing Sofosbuvir and Velpatasvir for oral use, marketed by Gilead Sciences, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store below 30 °C (86 ºF).
Key facts
- Active ingredient (INN)
- Sofosbuvir and Velpatasvir
- Brand
- Epclusa
- Strength
- 200 mg/50 mg
- Dosage form
- Oral pellets
- Route
- Oral
- Packs
- 28 packets
- Marketing authorisation holder
- Gilead Sciences
- Manufacturer
- Gilead Sciences
- Origin register
- US FDA, United States
- Storage
- Store below 30 °C (86 ºF).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AP55 Sofosbuvir and Velpatasvir
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 10 June 2021
- Identifiers
- RxCUI 1799212, 1799218, 2288814 +5DailyMed set ID 7f30631a-ee3b-4cfe-866b-964df3f0a44fNDC 61958-2204Application NDA214187
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 28 packet in 1 carton / 1 pellet in 1 packet | 61958-2204-1 | Gilead Sciences | 10 June 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Sofosbuvir and Velpatasvir
Clinical summary
Sofosbuvir and Velpatasvir is a fixed-dose combination of a hepatitis C virus NS5A inhibitor and a hepatitis C virus nucleotide analog NS5B polymerase inhibitor indicated for the treatment of adults, among other approved uses. MedsAcross supplies Sofosbuvir and Velpatasvir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Sofosbuvir and VelpatasvirFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Sofosbuvir and Velpatasvir prescribing information (Asegua Therapeutics) · U.S. National Library of Medicine, DailyMed
- Epclusa: European public assessment report (EPAR) · European Medicines Agency
Need Epclusa 200 mg/50 mg oral pellets for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.